Recent News

• 05.18.2026 - Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
• 05.13.2026 - Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
• 05.12.2026 - Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
• 05.07.2026 - Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Recent Filings

• 05.07.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.07.2026 - EX-99.1 EX-99.1
• 05.07.2026 - 8-K Current report
• 04.29.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.17.2026 - DEF 14A Other definitive proxy statements
• 04.17.2026 - ARS Annual Report to Security Holders
• 04.17.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.14.2026 - 144 Report of proposed sale of securities
• 04.06.2026 - 4 Statement of changes in beneficial ownership of securities
• 04.06.2026 - 4 Statement of changes in beneficial ownership of securities